Compare BHB & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHB | FDMT |
|---|---|---|
| Founded | 1887 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.6M | 513.6M |
| IPO Year | 1995 | 2019 |
| Metric | BHB | FDMT |
|---|---|---|
| Price | $33.01 | $9.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $36.00 | $34.13 |
| AVG Volume (30 Days) | 56.9K | ★ 690.4K |
| Earning Date | 04-20-2026 | 04-13-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | N/A | ★ $37,000.00 |
| Revenue This Year | $22.68 | $21,227.03 |
| Revenue Next Year | $3.66 | $161.87 |
| P/E Ratio | $20.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.43 | $2.24 |
| 52 Week High | $36.05 | $12.34 |
| Indicator | BHB | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 52.33 |
| Support Level | $28.35 | $8.88 |
| Resistance Level | $33.86 | $9.78 |
| Average True Range (ATR) | 1.03 | 0.53 |
| MACD | -0.32 | 0.00 |
| Stochastic Oscillator | 29.33 | 33.53 |
Bar Harbor Bankshares Inc is a bank holding company along with its subsidiaries that offers a full range of financial services products, brokerage services through third-party brokerage arrangements and also trust and investment management services to individuals, businesses, non-profit organizations, and municipalities. The company has following reportable segments such as Commercial construction, Commercial real estate owner occupied and non-owner occupied, Tax Exempt, Commercial and industrial loans, Residential real estate, Home equity and Consumer other. Its products and services consist of checking, deposits, cards, mobile banking, online services, loans, merchant services, trust, and fiduciary services, investment planning, education funding, individual retirement planning..
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.